AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10403876 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral palsy taking anticonvulsant medication
Number of subjects: 29
Study 10403876 — intervention group
Group type: COMPARATOR
Intervention: Control group (children without cerebral palsy)
Number of subjects: 29
Study 7738506 — intervention group
Group type: EXPERIMENTAL
Intervention: Inconsistent condition (reading sentences where the object was inconsistent with the protagonist's location)
Number of subjects: 0
Study 7738506 — intervention group
Group type: EXPERIMENTAL
Intervention: Mention of an object by means of an ambiguous pronoun
Number of subjects: 0
Study 7738506 — intervention group
Group type: COMPARATOR
Intervention: No specific intervention mentioned
Number of subjects: 0
Study 2160343 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium, cholesterol lowering diet (less than 60 mmol/day sodium, 30% energy from fat, high P/S ratio, 30-50 g/day fibre)
Number of subjects: 95
Study 2160343 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium, cholesterol maintaining diet (less than 60 mmol/day sodium)
Number of subjects: 95
Study 2160343 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium restriction
Number of subjects: 95
Study 2160343 — intervention group
Group type: COMPARATOR
Intervention: Sodium supplement (100 mmol/day NaCl)
Number of subjects: 95
Study 2160343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 432540 — intervention group
Group type: EXPERIMENTAL
Intervention: Parietal cell vagotomy (PCV)
Number of subjects: 37
Study 432540 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective vagotomy with pyloroplasty (SV + P)
Number of subjects: 37
Study 432540 — intervention group
Group type: COMPARATOR
Intervention: Control group (gastric resection)
Number of subjects: 37
Study 29986150 — intervention group
Group type: COMPARATOR
Intervention: 5 days of MCT alone (30 g·day‐1)
Number of subjects: 19
Study 29986150 — intervention group
Group type: COMPARATOR
Intervention: 1 session of 30 min of AE alone
Number of subjects: 19
Study 29986150 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 days of MCT and AE combined (MCT+AE)
Number of subjects: 19
Study 29986150 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 19
Study 29021908 — intervention group
Group type: EXPERIMENTAL
Intervention: Fustra20Neck&Back exercise program, individually guided neuromuscular exercise twice weekly for 10 weeks
Number of subjects: 0
Study 29021908 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 25546379 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose active (LDA) group: 500 mg of flaxseed hull extract containing 100 mg of secoisolariciresinol diglucoside (SDG), n=26
Number of subjects: 60
Study 25546379 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose active (HDA) group: 1000 mg of flaxseed hull extract containing 200 mg of secoisolariciresinol diglucoside (SDG), n=26
Number of subjects: 60
Study 25546379 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P) group: matching maltodextrin capsules, n=28
Number of subjects: 60
Study 23322362 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 μg/d)
Number of subjects: 92
Study 23322362 — intervention group
Group type: COMPARATOR
Intervention: Risedronate (35 mg/week)
Number of subjects: 92
Study 21301382 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of bevacizumab (1.25 mg/0.05 mL) every 4 weeks
Number of subjects: 20
Study 21301382 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control Group)
Number of subjects: 20
Study 19593148 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngopharyngeal Examination blade
Number of subjects: 81
Study 19593148 — intervention group
Group type: COMPARATOR
Intervention: English Macintosh blade
Number of subjects: 81
Study 17717918 — intervention group
Group type: EXPERIMENTAL
Intervention: Jianwei Yuyang Granule (JYG)
Number of subjects: 56
Study 17717918 — intervention group
Group type: COMPARATOR
Intervention: Famotidine and sucralfate (Control)
Number of subjects: 56
Study 15156385 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparoscopy
Number of subjects: 56
Study 15156385 — intervention group
Group type: COMPARATOR
Intervention: Computed Tomography (CT)
Number of subjects: 56
Study 11846050 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 610
Study 11846050 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 610
Study 11846050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 610
Study 9842609 — intervention group
Group type: EXPERIMENTAL
Intervention: LSD ingestion
Number of subjects: 3
Study 9842609 — intervention group
Group type: COMPARATOR
Intervention: Stationary magnets or removal of apparatus
Number of subjects: 3
Study 8042331 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal sclerotherapy (EVS)
Number of subjects: 149
Study 8042331 — intervention group
Group type: COMPARATOR
Intervention: Distal splenorenal shunt (DSRS)
Number of subjects: 149
Study 2635350 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate (ABM) 1.5 mg.kg-1
Number of subjects: 26
Study 2635350 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate (ABM) 2.25 mg.kg-1
Number of subjects: 26
Study 2635350 — intervention group
Group type: COMPARATOR
Intervention: Almitrine bismesylate (ABM) 0.75 mg.kg-1
Number of subjects: 26
Study 2635350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 370525 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (5 mg per day) during the luteal phase
Number of subjects: 8
Study 370525 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 8
Study 30866856 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DA‐α) injection (0.45 μg/kg once weekly subcutaneously)
Number of subjects: 126
Study 30866856 — intervention group
Group type: COMPARATOR
Intervention: EPO (50 IU/kg thrice weekly subcutaneously)
Number of subjects: 126
Study 28100192 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 3075
Study 28100192 — intervention group
Group type: COMPARATOR
Intervention: Other basal insulin regimens
Number of subjects: 3075
Study 27190323 — intervention group
Group type: EXPERIMENTAL
Intervention: Emapticap (0.5 mg/kg)
Number of subjects: 75
Study 27190323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 27190323 — intervention group
Group type: EXPERIMENTAL
Intervention: Emapticap
Number of subjects: 75
Study 27190323 — intervention group
Group type: EXPERIMENTAL
Intervention: Emapticap (post hoc analysis)
Number of subjects: 75
Study 24642133 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermaxillary fixation screw (IMFS)
Number of subjects: 50
Study 24642133 — intervention group
Group type: COMPARATOR
Intervention: Eyelet interdental wiring
Number of subjects: 50
Study 23093099 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on health promotion model (HPM)
Number of subjects: 165
Study 23093099 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 165
Study 19398783 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC)
Number of subjects: 440
Study 19398783 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (enoxaparin)
Number of subjects: 440
Study 19398783 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (control)
Number of subjects: 440
Study 19398783 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated compression stockings (GCS)
Number of subjects: 440
Study 17966757 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone 200 mg tablet with food
Number of subjects: 0
Study 17966757 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone 200 mg tablet without food
Number of subjects: 0
Study 15554767 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 92
Study 15554767 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 92
Study 15554767 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 92
Study 15554767 — intervention group
Group type: EXPERIMENTAL
Intervention: Perospirone
Number of subjects: 92
Study 15554767 — intervention group
Group type: COMPARATOR
Intervention: Conventional antipsychotic drugs
Number of subjects: 92
Study 14588350 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumented posterior lumbar interbody fusion (PLIF)
Number of subjects: 29
Study 14588350 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative management (spinal extensor muscle-strengthening exercise, medications, and restricted duty)
Number of subjects: 29
Study 9636566 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral (cyclosporine)
Number of subjects: 0
Study 9636566 — intervention group
Group type: COMPARATOR
Intervention: Prograf (tacrolimus)
Number of subjects: 0
Study 7512336 — intervention group
Group type: EXPERIMENTAL
Intervention: Krypton laser treatment for AMD
Number of subjects: 300
Study 7512336 — intervention group
Group type: EXPERIMENTAL
Intervention: Krypton laser treatment for ocular histoplasmosis
Number of subjects: 300
Study 7512336 — intervention group
Group type: EXPERIMENTAL
Intervention: Krypton laser treatment for idiopathic choroidal neovascularization
Number of subjects: 300
Study 7512336 — intervention group
Group type: EXPERIMENTAL
Intervention: Krypton laser treatment for normotensive patients with AMD
Number of subjects: 300
Study 7512336 — intervention group
Group type: EXPERIMENTAL
Intervention: Krypton laser treatment for hypertensive patients with AMD
Number of subjects: 300
Study 2974719 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% benzoyl peroxide gel (Benzac W5)
Number of subjects: 0
Study 2974719 — intervention group
Group type: COMPARATOR
Intervention: 1% clindamycin phosphate solution (Cleocin T)
Number of subjects: 0
Study 29555214 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia experiencing MI
Number of subjects: 0
Study 29555214 — intervention group
Group type: COMPARATOR
Intervention: Schizophrenia controls (experiencing MI)
Number of subjects: 0
Study 29555214 — intervention group
Group type: COMPARATOR
Intervention: MI controls (general population experiencing MI)
Number of subjects: 0
Study 29555214 — intervention group
Group type: COMPARATOR
Intervention: Controls not experiencing MI
Number of subjects: 0
Study 29555214 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia
Number of subjects: 0
Study 29555214 — intervention group
Group type: COMPARATOR
Intervention: MI controls
Number of subjects: 0
Study 28485467 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Needle Tip Positioning (DNTP) ultrasound technique
Number of subjects: 50
Study 28485467 — intervention group
Group type: COMPARATOR
Intervention: Palpation technique
Number of subjects: 50
Study 26168743 — intervention group
Group type: EXPERIMENTAL
Intervention: Methocarbamol (Ortoton), orally administered for up to 8 days
Number of subjects: 202
Study 26168743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 26168743 — intervention group
Group type: EXPERIMENTAL
Intervention: Methocarbamol (Ortoton)
Number of subjects: 202
Study 23972027 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver training intervention
Number of subjects: 0
Study 21347990 — intervention group
Group type: EXPERIMENTAL
Intervention: Following another person making deliberate skin‐crossing saccades between the outside area and the tumour from multiple angles
Number of subjects: 150
Study 21347990 — intervention group
Group type: EXPERIMENTAL
Intervention: Following another person making natural skin‐crossing saccades between the outside area and the tumour from multiple angles
Number of subjects: 150
Study 21347990 — intervention group
Group type: COMPARATOR
Intervention: Focusing solely on the central tumour
Number of subjects: 150
Study 18355507 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cariporide (180 mg in a 1-hour preoperative loading dose, then 40 mg per hour over 24 hours and 20 mg per hour over the subsequent 24 hours)
Number of subjects: 5761
Study 18355507 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cariporide
Number of subjects: 5761
Study 18355507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5761
Study 16328116 — intervention group
Group type: EXPERIMENTAL
Intervention: Monarc
Number of subjects: 60
Study 16328116 — intervention group
Group type: COMPARATOR
Intervention: Sparc
Number of subjects: 60
Study 12609781 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymecycline 300 mg od
Number of subjects: 271
Study 12609781 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymecycline 150 mg bid
Number of subjects: 271
Study 12609781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study 15184612 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,4-diaminopyridine (3,4-DAP)
Number of subjects: 12
Study 15184612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10396008 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (pharmacotherapy + cognitive‐behavioral psychotherapy)
Number of subjects: 26
Study 10396008 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 26
Study 7555472 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination group (insulin + OHAs)
Number of subjects: 53
Study 7555472 — intervention group
Group type: COMPARATOR
Intervention: Insulin group (insulin alone)
Number of subjects: 53
Study 7555472 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 53
Study 2100046 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine (different doses, subcutaneously)
Number of subjects: 25
Study 2100046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 395630 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g intravenously six times daily for a maximum of 3 days, followed by 1.5 g orally four times daily for a maximum of 4 days)
Number of subjects: 149
Study 395630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 395630 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 149
Study 28942691 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal cervical length measurement at 16-20 weeks gestation
Number of subjects: 178
Study 28045793 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention units received unit-level violence data to facilitate development of an action plan for violence prevention
Number of subjects: 41
Study 28045793 — intervention group
Group type: COMPARATOR
Intervention: Control units received no data
Number of subjects: 41
Study 28045793 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention units received unit-level violence data
Number of subjects: 41
Study 25964070 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg daily
Number of subjects: 1791
Study 25964070 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 8 mg daily
Number of subjects: 1791
Study 25964070 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg and 8 mg daily
Number of subjects: 1791
Study 23563932 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 80
Study 23563932 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D use
Number of subjects: 80
Study 23563932 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ADT)
Number of subjects: 80
Study 21271509 — intervention group
Group type: EXPERIMENTAL
Intervention: Single stage TKA
Number of subjects: 78
Study 21271509 — intervention group
Group type: COMPARATOR
Intervention: Two-stage TKA
Number of subjects: 78
Study 21271509 — intervention group
Group type: EXPERIMENTAL
Intervention: Stolzalpen knee score
Number of subjects: 78
Study 19166691 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe 10 mg/day (monotherapy)
Number of subjects: 5261
Study 19166691 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe 10 mg/day (add-on to statin therapy)
Number of subjects: 5261
Study 17952525 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein mesh hernioplasty (LMH)
Number of subjects: 651
Study 17952525 — intervention group
Group type: EXPERIMENTAL
Intervention: Moloney darn repair (MDR)
Number of subjects: 651
Study 17952525 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MDR and LMH
Number of subjects: 651
Study 15485009 — intervention group
Group type: EXPERIMENTAL
Intervention: TAMMEF (Therapeutic Application of a Musically Modulated Electromagnetic Field)
Number of subjects: 90
Study 15485009 — intervention group
Group type: EXPERIMENTAL
Intervention: ELF (Extremely Low Frequencies)
Number of subjects: 90
Study 15485009 — intervention group
Group type: COMPARATOR
Intervention: Simulated field (Control group)
Number of subjects: 90
Study 11295785 — intervention group
Group type: EXPERIMENTAL
Intervention: lisuride
Number of subjects: 0
Study 11295785 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 9174320 — intervention group
Group type: EXPERIMENTAL
Intervention: Train-of-four (TOF) stimulation
Number of subjects: 105
Study 9174320 — intervention group
Group type: EXPERIMENTAL
Intervention: Double burst stimulation (DBS3,3)
Number of subjects: 105
Study 9174320 — intervention group
Group type: EXPERIMENTAL
Intervention: Double burst stimulation (DBS3,2)
Number of subjects: 105
Study 9174320 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline displacement measurement
Number of subjects: 105
Study 7947499 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent electronic fetal monitoring (I-group)
Number of subjects: 4044
Study 7947499 — intervention group
Group type: COMPARATOR
Intervention: Continuous electronic fetal monitoring (C-group)
Number of subjects: 4044
Study 7947499 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (I-group and C-group)
Number of subjects: 4044
Study 29634656 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolastin C, plasma-derived AAT, at 60 mg/kg infused intravenously within 12 hours of reperfusion
Number of subjects: 10
Study 27513506 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterols (2.24 g daily) in skim milk (350 ml twice daily) for 3 weeks
Number of subjects: 54
Study 27513506 — intervention group
Group type: COMPARATOR
Intervention: Control group received the same amount of skim milk without plant sterols
Number of subjects: 54
Study 25534171 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=166)
Number of subjects: 350
Study 25534171 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=184)
Number of subjects: 350
Study 23038067 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous pain registration procedure using electronic VAS
Number of subjects: 28
Study 20518266 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolene mesh (anterior and posterior prolift)
Number of subjects: 500
Study 20518266 — intervention group
Group type: COMPARATOR
Intervention: Sacrospinous fixation
Number of subjects: 500
Study 20518266 — intervention group
Group type: EXPERIMENTAL
Intervention: All surgical techniques (including Prolene mesh and sacrospinous fixation)
Number of subjects: 500
Study 18384590 — intervention group
Group type: EXPERIMENTAL
Intervention: Care manager home environment assessment
Number of subjects: 238
Study 18384590 — intervention group
Group type: EXPERIMENTAL
Intervention: Linking caregivers to community agencies for nonspecific needs
Number of subjects: 238
Study 18384590 — intervention group
Group type: COMPARATOR
Intervention: No specific care management activities
Number of subjects: 238
Study 16554145 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg the day before and 1200 mg on race day)
Number of subjects: 54
Study 12610048 — intervention group
Group type: COMPARATOR
Intervention: Neither diabetes nor NF-CVD
Number of subjects: 11645
Study 12610048 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes only
Number of subjects: 11645
Study 12610048 — intervention group
Group type: EXPERIMENTAL
Intervention: NF-CVD only
Number of subjects: 11645
Study 12610048 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diabetes and NF-CVD
Number of subjects: 11645
Study 12610048 — intervention group
Group type: EXPERIMENTAL
Intervention: NF-CVD
Number of subjects: 11645
Study 12610048 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants on hypoglycemic agents
Number of subjects: 11645
Study 10771455 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 40 mg + Cimetidine 800 mg
Number of subjects: 11
Study 10771455 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 40 mg + Maalox
Number of subjects: 11
Study 10771455 — intervention group
Group type: COMPARATOR
Intervention: Ziprasidone 40 mg alone
Number of subjects: 11
Study 9238880 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaq & White125 electric toothbrush
Number of subjects: 0
Study 9238880 — intervention group
Group type: COMPARATOR
Intervention: Oral‐B 35 manual toothbrush (Control)
Number of subjects: 0
Study 1450081 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard protocol treatment
Number of subjects: 14315
Study 1450081 — intervention group
Group type: COMPARATOR
Intervention: Randomized trials
Number of subjects: 14315
Study 1450081 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol (non-randomized)
Number of subjects: 14315
Study 2413686 — intervention group
Group type: EXPERIMENTAL
Intervention: Benoxaprofen
Number of subjects: 0
Study 2413686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30172030 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive identification of joint position (first experiment)
Number of subjects: 30
Study 30172030 — intervention group
Group type: COMPARATOR
Intervention: Kinaesthetic movement reproduction (second experiment)
Number of subjects: 30
Study 26852885 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training (6 resistance exercises + 30 min aerobic exercise, 3 days/week for 12 weeks)
Number of subjects: 33
Study 26852885 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training
Number of subjects: 33
Study 26852885 — intervention group
Group type: COMPARATOR
Intervention: Control group (overweight girls, no intervention)
Number of subjects: 33
Study 26852885 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight group (n=15)
Number of subjects: 33